BioSpace News Archive

Alegeus, the market leader in consumer-directed healthcare (CDH) solutions, today announced a partnership with HealthPoint Plus, a subscription-based telehealth provider that connects patients to state-licensed, board-certified doctors anytime, anywhere.

ACADIA Pharmaceuticals to Present at the Goldman Sachs 41 st Annual Global Healthcare Conference on June 9, 2020

Attivo Networks®, an award-winning leader in deception for cybersecurity threat detection, today announced its participation with SINC and MIT Sloan on a research report entitled “The Cybersecurity Landscape: Challenges and How to Overcome Them.

ExSight Ventures Leads First Close Financing Round, alongside InFocus Capital, to Support Pre-clinical Development of Sustained Release Biologic and Small Molecule Therapeutics; Visionary Ventures Leads Second Close Financing

Know Labs, Inc. an emerging leader in non-invasive medical diagnostics, announced that it closed a financing round on May 26, 2020.

PCI Pharma Services (PCI) , a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, and Experic , a contract manufacturing organization (CMO) and pharmaceutical supply service company, are joining forces with a strategic, synergistic partnership involving clinical and commercial m

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the revised schedule for completion of the ARISE-3 dry eye clinical trial, http://www.regenerx.com/2020-06-02-June-2-2020-Advi

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is excited to announce the publication of a health economic study in Wound Management and Prevention, which states that the use of PICO™ Single Use Negative Pressure Wound Therapy System (sNPWT) is estimated to be highly cost effective when compared with traditional NPWT (tNPWT),

Meditrina, Inc., a premier women’s healthcare company and developer of the state-of-the-art Aveta™ System, for the treatment of intrauterine pathologies such as polyps, fibroids, and/or RPOC, announced today that it has completed a $10 million equity financing as a first tranche of a $20- million commercialization round. The fina

Echo® MS System delivers ultra-high throughput screening to redefine high-throughput quantification of molecules